AXIM BIOTECHNOLOGIES, INC.— Sankey Diagram
Quarterly mode · period ending 2024-06-30 · SEC EDGAR
ComparingFY2024 (Q4) vs FY2023 (Q4)
Revenue
$17K
↑+76.0% +$8Kvs FY2023 (Q4)
Gross Profit
$16K
↑+58.5% +$6Kvs FY2023 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2024 (Q4) | FY2023 (Q4) |
|---|---|---|
| Revenue | $17K | $10K |
| COGS | $2K | $0 |
| Gross Profit | $16K | $10K |
| R&D | $4K | $34K |
| SG&A | $473K | $567K |
| D&A | $108K | $107K |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · AXIM · Comparing FY2024 (Q4) vs FY2023 (Q4)